

Good risk-reward with EUR vega bear steepeners

Entering a vega-slide trade at levels rarely seen

We recommend a 5y2y1y ATMF – 5y10y20y ATMF-23bp zero-cost, dv01-neutral bear steepener. The spot spread, which closely mirrors the 2s30s slope, is now at 229bp. The significant carry priced into the curve places 5yr forwards at -3.7bp and the large vol differential makes for a strike spread of -26.7bp. Although we believe some flattening is inevitable, the significant buffer for flattening makes for a trade with a high likelihood of paying off and good carry for the next few years.

EUR 5y1y2y – 5y10y20y bear steepeners

The standard view on Europe is that curves will likely remain steep in the short run, given the relatively sluggish economy and continuing slow recovery. But this tentative recovery may also gather steam and cause the curve to flatten. In spite of this, the significant carry embedded in this bear steepening trade means that it should be able easily to withstand much more flattening than is likely to happen over the course of the next few years. We recommend the following trade:

Buy €9.3mn 5y10y20y ATMF-25bp payers and sell €55.0mn 5y1y2y ATMF payers for zero cost.

Fig. 1: Enter 5y1y2y vs 5y10y20y conditional bear steepeners for €10k/bp

EUR Bear Steeper 5y1y2y vs 5y10y20y, €10k/bp			
	Midcurve 5y1y2y	Midcurve	Spread (bp)
Spot	0.78%	3.06%	228.6
Forward	2.88%	2.84%	-3.8
Strike	2.88%	2.61%	-26.8
	ATMF	ATMF-23	ATMF-23
Pickup (bp)			
Fwd-Spot	-210	22	232
Vol	0	23	23
Total	-210	45	255
Z-Scores: Spot Vol-Normalized Pickup (no units)			
Fwd-Spot	-1.45	0.16	
Vol	0.00	0.17	
Total	-1.45	0.33	
Prob(Fwd(T)>Strike)	7.4%	62.8%	
Conditional Valuation and Premia (EUR)			
PV	695,437	695,437	0
Expected Value	579,284	677,464	98,180
Premium	-16.7%	-2.6%	

Source: Nomura Research

As we see in Figure 1, the short 5y1y2y payer leg is struck ATMF (which is 211bp above the current spot 1y2y rates), carrying negatively. Meanwhile, the long 5y10y20y ATMF-23bp is struck at 2.61%, below forwards at 2.84% and a full 45bp below spot. Combined, this makes for a total of 255.7bp of carry. We note that, given the relative vol of the 5y1y2y and the 5y10y20y (where we consider rates centred at spot with spot vol to allow us to consider the carry), the long leg has a 63% probability of expiring ITM while the

Global Markets Research

30 January 2014

Research analysts

Quantitative Strategies

Nick Firoozye - Nlplc
nick.firoozye@nomura.com
+44 20 7102 1660


Qilong Zhang - NIHK
qilong.zhang@nomura.com
+852 2252 6191

short leg has only a 7% probability. Similarly, valuing using our basic valuation method¹, we find the short leg to have lost far more value than the long leg, resulting in a positive expected gain.

The rationale is quite straightforward. As we note in Figure 2, the 10y20y-1y2y spread mimics 2s30s. The slope does not necessarily appear level dependent as some of the steepest slopes in the past 10 years occurred when the Bund was between 3.5% and 4.5%.

Fig. 2: 10y20y-1y2y spread mirrors 2s30s slope

Negative only in the peak of the crisis with almost no relationship to levels



Source: Nomura Research, Bloomberg

More telling is the fact the curve flattened through the strikes only very briefly, during the height of the crisis. We present this past 10 years of data (2528 trading days) in Figure 3. As we note, inversions through the strikes happened on some 24-26 days, and of them, at least 17 hit -35bp and 10 hit -45bp. These were extreme times, which of course could always happen, but we note that this was during the era of Bear Stearns' problems, the mistake ECB hike of July 2008 (and subsequent severe inversion of all slopes given BuBa President Max Weber's preannouncement of the policy move) and the later Lehman bankruptcy.

Fig. 3: Percentage of days that 1y2y-10y20y inverted (over 10 years or 2528 trading days)

Inversions tend to be only extreme, and only during severe crises.

Level (bp)	Days < Level	Prob(< Level)
0	58	2.29%
-5	53	2.10%
-10	46	1.82%
-15	35	1.38%
-20	30	1.19%
-25	26	1.03%
-30	24	0.95%
-35	17	0.67%
-40	14	0.55%
-45	10	0.40%
-50	8	0.32%
-55	4	0.16%
-60	3	0.12%
-65	1	0.04%

Source: Nomura Research

Looking at the more positive side, we think it altogether likely that this trade will terminate in the money, given the significant portion of time for which slopes have remained elevated. In Figure 4, we see the fraction of history when the slopes have been steep, noting that for more than 50% of the history it has been over 150bp steep.

¹ Probabilities and expected values are computed assuming that rates are normal, centred at spot and standard deviation as the corresponding spot vol multiplied by the square root of the expiry. This basic version of a P-measure (physical as opposed to Q-measure or risk-neutral) is consistent with carry (where spot is realised) and academic research which shows that the best single predictor of realised volatility is implied volatility.

Fig. 4: 1y2y 10y20y is usually relatively steep

Mostly steepening trades would result in positive P&L

Level (bp)	Days > Level	Prob(> Level)
200	513	20.29%
175	862	34.10%
150	1249	49.41%
125	1549	61.27%
100	1770	70.02%
75	1985	78.52%
50	2153	85.17%
25	2364	93.51%
0	2470	97.71%

Source: Nomura Research


Finally, just running a back-test, we know (as one should expect) that for 96.2% of the past ten years of history the trade would have made money, for 2.85% of the time it would have expired worthless, and 0.95% of the time it would have lost money, if held to term.

Entry times and pricing rationale

We have a number of different reasons for putting on the trade at this time, but a major one is because of the significant vol differential priced into the upper left corner (1y2y vols) and the lower right corner (10y20y vols). This is partly due to the callable issuance which depresses lower left vols. Meanwhile, significant rate hike expectations have raised the premium at the lower right. We can see these two effects in Figure 5.

Fig. 5: ATM vol differential at a recent peak

Adding to the attraction of the trade




Source: Nomura Research

The carry built into the forwards is not as infrequent, and we can see in Figure 6 that it has often been this large, and the steeper the curve typically the higher the carry. Nonetheless, at 229bp we are not far off the recent peak (on 21 Nov 2013) of 254bp, which was a three-year high. The combined vol differential and the significant carry of the trade should both add to the attractions of this bear steepener, also giving us comfort that the current entry levels are likely to be among the best of the recent past.

Fig. 6: Levels and 5yr carry in bp

At 233bp, just off the 21 Nov 2013 peak of 254bp, which was a three-year record.



Source: Nomura Research

Carry and risks

As we have explained the trade can be carried to term and would likely expire in the money. Many investors may consider the trade for shorter than five-year horizons. In Figure 7 we show the package (at €10k/bp) with each leg priced. The roll (in rows below the Spot entry) shows that while both legs lose money (the long leg has positive carry but negative theta as we have explained) the package gains, with the biggest gains between years two and three. Given this analysis, we think the trade looks attractive on a three- to four-year horizon.

Fig. 7: PV and rolldown

Negative carry for the short leg and positive carry (but negative theta) for the long leg

Horizon	5y1y2y	5y10y20y	Package
Spot (PV)	695,495	695,495	0
1Y	-169,705	-38,274	131,431
2Y	-354,993	-56,381	298,612
3Y	-523,984	-86,829	437,155
4Y	-668,886	-142,064	526,822
5Y	-695,495	-168,722	526,773

Source: Nomura Research

Finally, we show the risks to the trade in Figure 8. As we see, the trade is short vega (since the short leg is ATMF while the long leg has lower vega being ITM) and similarly short gamma, each of which could affect the P&L if it is taken off before expiry.

Fig. 8: Risks to the trade

Modestly short vega and short gamma (from ATMF short leg, rather than the ITM long leg), are the largest Greeks

EUR Bear Steepener 5y1y2y vs 5y10y20y, €10k/bp Trade Risks									
Trade	Notional €	Spot %	Fwd %	Strike	Premium	Delta €/bp	Vega €/bp	Gamma €/bp2	
Payer Midcurve 5y1y2y	-55MM	0.77	2.88	ATMF	-695,495	-3,482	-10,824	-20	
Payer Midcurve 5y10y20y	9MM	3.06	2.84	ATMF-25	695,495	3,948	9,051	17	
		2.29	-0.04	ATMF-25		467	-1773	-3	

Source: Nomura Research

Trade Idea: Buy €9.3mn 5y10y20y ATMF-23bp (261bp) payers and sell €55.0mn 5y1y2y ATMF (77bp) payers for zero cost.

Appendix A-1

Analyst Certification

I, Nick Firoozye, hereby certify (1) that the views expressed in this Research report accurately reflect my personal views about any or all of the subject securities or issuers referred to in this Research report, (2) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this Research report and (3) no part of my compensation is tied to any specific investment banking transactions performed by Nomura Securities International, Inc., Nomura International plc or any other Nomura Group company.

Important Disclosures

Online availability of research and conflict-of-interest disclosures

Nomura research is available on www.nomuranow.com/research, Bloomberg, Capital IQ, Factset, MarkitHub, Reuters and ThomsonOne. Important disclosures may be read at <http://go.nomuranow.com/research/globalresearchportal/pages/disclosures/disclosures.aspx> or requested from Nomura Securities International, Inc., on 1-877-865-5752. If you have any difficulties with the website, please email grpsupport@nomura.com for help.

The analysts responsible for preparing this report have received compensation based upon various factors including the firm's total revenues, a portion of which is generated by Investment Banking activities. Unless otherwise noted, the non-US analysts listed at the front of this report are not registered/qualified as research analysts under FINRA/NYSE rules, may not be associated persons of NSI, and may not be subject to FINRA Rule 2711 and NYSE Rule 472 restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account.

Nomura Global Financial Products Inc. ("NGFP") Nomura Derivative Products Inc. ("NDPI") and Nomura International plc. ("Nlplc") are registered with the Commodities Futures Trading Commission and the National Futures Association (NFA) as swap dealers. NGFP, NDPI, and Nlplc are generally engaged in the trading of swaps and other derivative products, any of which may be the subject of this report.

ADDITIONAL DISCLOSURES REQUIRED IN THE U.S.

Principal Trading: Nomura Securities International, Inc and its affiliates will usually trade as principal in the fixed income securities (or in related derivatives) that are the subject of this research report. Analyst Interactions with other Nomura Securities International, Inc. Personnel: The fixed income research analysts of Nomura Securities International, Inc and its affiliates regularly interact with sales and trading desk personnel in connection with obtaining liquidity and pricing information for their respective coverage universe.

Valuation methodology - Fixed Income

Nomura's Fixed Income Strategists express views on the price of securities and financial markets by providing trade recommendations. These can be relative value recommendations, directional trade recommendations, asset allocation recommendations, or a mixture of all three. The analysis which is embedded in a trade recommendation would include, but not be limited to:

- Fundamental analysis regarding whether a security's price deviates from its underlying macro- or micro-economic fundamentals.
- Quantitative analysis of price variations.
- Technical factors such as regulatory changes, changes to risk appetite in the market, unexpected rating actions, primary market activity and supply/ demand considerations.

The timeframe for a trade recommendation is variable. Tactical ideas have a short timeframe, typically less than three months. Strategic trade ideas have a longer timeframe of typically more than three months.

Disclaimers

This document contains material that has been prepared by the Nomura entity identified at the top or bottom of page 1 herein, if any, and/or, with the sole or joint contributions of one or more Nomura entities whose employees and their respective affiliations are specified on page 1 herein or identified elsewhere in the document. The term "Nomura Group" used herein refers to Nomura Holdings, Inc. or any of its affiliates or subsidiaries and may refer to one or more Nomura Group companies including: Nomura Securities Co., Ltd. ('NSC') Tokyo, Japan; Nomura International plc ('Nlplc'), UK; Nomura Securities International, Inc. ('NSI'), New York, US; Nomura International (Hong Kong) Ltd. ('NIHK'), Hong Kong; Nomura Financial Investment (Korea) Co., Ltd. ('NFIK'), Korea (Information on Nomura analysts registered with the Korea Financial Investment Association ('KOFIA') can be found on the KOFIA Intranet at <http://dis.kofia.or.kr>); Nomura Singapore Ltd. ('NSL'), Singapore (Registration number 197201440E, regulated by the Monetary Authority of Singapore); Nomura Australia Ltd. ('NAL'), Australia (ABN 48 003 032 513), regulated by the Australian Securities and Investment Commission ('ASIC') and holder of an Australian financial services licence number 246412; P.T. Nomura Indonesia ('PTNI'), Indonesia; Nomura Securities Malaysia Sdn. Bhd. ('NSM'), Malaysia; NIHK, Taipei Branch ('NITB'), Taiwan; Nomura Financial Advisory and Securities (India) Private Limited ('NFASL'), Mumbai, India (Registered Address: Ceejay House, Level 11, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai- 400 018, India; Tel: +91 22 4037 4037, Fax: +91 22 4037 4111; SEBI Registration No: BSE INB011299030, NSE INB231299034, INF231299034, INE 231299034, MCX: INE261299034) and Nlplc, Madrid Branch ('Nlplc, Madrid'). 'CNS Thailand' next to an analyst's name on the front page of a research report indicates that the analyst is employed by Capital Nomura Securities Public Company Limited ('CNS') to provide research assistance services to NSL under a Research Assistance Agreement. CNS is not a Nomura entity.

THIS MATERIAL IS: (I) FOR YOUR PRIVATE INFORMATION, AND WE ARE NOT SOLICITING ANY ACTION BASED UPON IT; (II) NOT TO BE CONSTRUED AS AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITY IN ANY JURISDICTION WHERE SUCH OFFER OR SOLICITATION WOULD BE ILLEGAL; AND (III) BASED UPON INFORMATION FROM SOURCES THAT WE CONSIDER RELIABLE, BUT HAS NOT BEEN INDEPENDENTLY VERIFIED BY NOMURA GROUP.

Nomura Group does not warrant or represent that the document is accurate, complete, reliable, fit for any particular purpose or merchantable and does not accept liability for any act (or decision not to act) resulting from use of this document and related data. To the maximum extent permissible all warranties and other assurances by Nomura group are hereby excluded and Nomura Group shall have no liability for the use, misuse, or distribution of this information.

Opinions or estimates expressed are current opinions as of the original publication date appearing on this material and the information, including the opinions and estimates contained herein, are subject to change without notice. Nomura Group is under no duty to update this document.

Any comments or statements made herein are those of the author(s) and may differ from views held by other parties within Nomura Group. Clients should consider whether any advice or recommendation in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. Nomura Group does not provide tax advice.

Nomura Group, and/or its officers, directors and employees, may, to the extent permitted by applicable law and/or regulation, deal as principal, agent, or otherwise, or have long or short positions in, or buy or sell, the securities, commodities or instruments, or options or other derivative instruments based thereon, of issuers or securities mentioned herein. Nomura Group companies may also act as market maker or liquidity provider (within the meaning of applicable regulations in the UK) in the financial instruments of the issuer. Where the activity of market maker is carried out in accordance with the definition given to it by specific laws and regulations of the US or other jurisdictions, this will be separately disclosed within the specific issuer disclosures.

This document may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information, including ratings, and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice.

Any MSCI sourced information in this document is the exclusive property of MSCI Inc. ('MSCI'). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, re-disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI and the MSCI indexes are services marks of MSCI and its affiliates.

Investors should consider this document as only a single factor in making their investment decision and, as such, the report should not be viewed as identifying or suggesting all risks, direct or indirect, that may be associated with any investment decision. Nomura Group produces a number of different types of research product including, among others, fundamental analysis, quantitative analysis and short term trading ideas; recommendations contained in one type of research product may differ from recommendations contained in other types of research product, whether as a result of differing time horizons, methodologies or otherwise. Nomura Group publishes research product in a number of different ways including the posting of product on Nomura Group portals and/or distribution directly to clients. Different groups of clients may receive different products and services from the research department depending on their individual requirements. Clients outside of the US may access the Nomura Research Trading Ideas platform (Retina) at <http://go.nomuranow.com/equities/tradingideas/retina/>

Figures presented herein may refer to past performance or simulations based on past performance which are not reliable indicators of future performance. Where the information contains an indication of future performance, such forecasts may not be a reliable indicator of future performance. Moreover, simulations are based on models and simplifying assumptions which may oversimplify and not reflect the future distribution of returns.

Certain securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of, or income derived from, the investment.

The securities described herein may not have been registered under the US Securities Act of 1933 (the '1933 Act'), and, in such case, may not be offered or sold in the US or to US persons unless they have been registered under the 1933 Act, or except in compliance with an exemption from the registration requirements of the 1933 Act. Unless governing law permits otherwise, any transaction should be executed via a Nomura entity in your home jurisdiction.

This document has been approved for distribution in the UK and European Economic Area as investment research by Nlplc. Nlplc is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. Nlplc is a member of the London Stock Exchange. This document does not constitute a personal recommendation within the meaning of applicable regulations in the UK, or take into account the particular investment objectives, financial situations, or needs of individual investors. This document is intended only for investors who are 'eligible counterparties' or 'professional clients' for the purposes of applicable regulations in the UK, and may not, therefore, be redistributed to persons who are 'retail clients' for such purposes. This document has been approved by NHHK, which is regulated by the Hong Kong Securities and Futures Commission, for distribution in Hong Kong by NHHK. This document has been approved for distribution in Australia by NAL, which is authorized and regulated in Australia by the ASIC. This document has also been approved for distribution in Malaysia by NSM. In Singapore, this document has been distributed by NSL. NSL accepts legal responsibility for the content of this document, where it concerns securities, futures and foreign exchange, issued by their foreign affiliates in respect of recipients who are not accredited, expert or institutional investors as defined by the Securities and Futures Act (Chapter 289). Recipients of this document in Singapore should contact NSL in respect of matters arising from, or in connection with, this document. Unless prohibited by the provisions of Regulation S of the 1933 Act, this material is distributed in the US, by NSI, a US-registered broker-dealer, which accepts responsibility for its contents in accordance with the provisions of Rule 15a-6, under the US Securities Exchange Act of 1934.

This document has not been approved for distribution to persons other than 'Authorised Persons', 'Exempt Persons' or 'Institutions' (as defined by the Capital Markets Authority) in the Kingdom of Saudi Arabia ('Saudi Arabia') or 'professional clients' (as defined by the Dubai Financial Services Authority) in the United Arab Emirates ('UAE') or a 'Market Counterparty' or 'Business Customers' (as defined by the Qatar Financial Centre Regulatory Authority) in the State of Qatar ('Qatar') by Nomura Saudi Arabia, Nlplc or any other member of Nomura Group, as the case may be. Neither this document nor any copy thereof may be taken or transmitted or distributed, directly or indirectly, by any person other than those authorised to do so into Saudi Arabia or in the UAE or in Qatar or to any person other than 'Authorised Persons', 'Exempt Persons' or 'Institutions' located in Saudi Arabia or 'professional clients' in the UAE or a 'Market Counterparty' or 'Business Customers' in Qatar. By accepting to receive this document, you represent that you are not located in Saudi Arabia or that you are an 'Authorised Person', an 'Exempt Person' or an 'Institution' in Saudi Arabia or that you are a 'professional client' in the UAE or a 'Market Counterparty' or 'Business Customers' in Qatar and agree to comply with these restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the UAE or Saudi Arabia or Qatar.

NO PART OF THIS MATERIAL MAY BE (I) COPIED, PHOTOCOPIED, OR DUPLICATED IN ANY FORM, BY ANY MEANS; OR (II) REDISTRIBUTED WITHOUT THE PRIOR WRITTEN CONSENT OF A MEMBER OF NOMURA GROUP. If this document has been distributed by electronic transmission, such as e-mail, then such transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of this document, which may arise as a result of electronic transmission. If verification is required, please request a hard-copy version.

Nomura Group manages conflicts with respect to the production of research through its compliance policies and procedures (including, but not limited to, Conflicts of Interest, Chinese Wall and Confidentiality policies) as well as through the maintenance of Chinese walls and employee training.

Additional information is available upon request and disclosure information is available at the Nomura Disclosure web page:

<http://go.nomuranow.com/research/globalresearchportal/pages/disclosures/disclosures.aspx>

Copyright © 2014 Nomura International plc. All rights reserved.